Analysis of antiviral drug properties of thymidine kinase of herpes B virus using recombinant herpes simplex virus 1

Microbiol Spectr. 2024 Jan 11;12(1):e0309123. doi: 10.1128/spectrum.03091-23. Epub 2023 Dec 14.

Abstract

Zoonotic infection of humans with herpes B virus (BV) causes severe neurological diseases. Acyclovir (ACV) and ganciclovir (GCV), most frequently used as anti-herpes drugs, are recommended for prophylaxis and therapy in human BV infection. In this study, we examined the property of BV thymidine kinase (TK) against anti-herpes drugs using a recombinant herpes simplex virus type 1 (HSV-1) carrying BV TK gene. We found that HSV-1 carrying BV TK was similarly sensitive to GCV as HSV-1 carrying varicella zoster virus TK. In addition, we demonstrated that BV TK was not mutated in the GCV- and ACV-resistant HSV-1 carrying BV TK, suggesting that ACV- or GCV-resistant BV might be rare during treatment with these antiviral drugs. These data can provide a new insight into the properties of BV TK in terms of the development of drug resistance.

Keywords: B virus; DNA polymerase; acyclovir; acyclovir resistant; ganciclovir; ganciclovir resistant; herpes simplex virus 1; thymidine kinases.

MeSH terms

  • Acyclovir / pharmacology
  • Acyclovir / therapeutic use
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Ganciclovir / pharmacology
  • Herpes Simplex* / drug therapy
  • Herpesvirus 1, Cercopithecine*
  • Herpesvirus 1, Human* / genetics
  • Humans
  • Thymidine Kinase / genetics
  • Thymidine Kinase / therapeutic use

Substances

  • Antiviral Agents
  • Thymidine Kinase
  • Acyclovir
  • Ganciclovir